newsfilter
← Latest News
Business Wire·

Pivotal Trial of EndeavorRxⓇ in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes

Attention improvements were nearly three times as large as those in the pivotal trial that served as the basis for EndeavorRx's FDA authorization for children with ADHD ages 8-12 Study data will be used to file for